- Author:
Jiang Ying YAN
1
;
Xiao Lu NIE
;
Qing Mei TAO
;
Si Yan ZHAN
;
Yan De ZHANG
Author Information
- Publication Type:Journal Article
- Keywords: Hepatotoxicity; Ketoconazole; Oral treatment; Systematic review
- MeSH: Antifungal Agents; administration & dosage; adverse effects; Chemical and Drug Induced Liver Injury; etiology; Humans; Ketoconazole; administration & dosage; adverse effects; Off-Label Use
- From: Biomedical and Environmental Sciences 2013;26(7):605-610
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo evaluate the incidence of Ketoconazole associated hepatotoxicity and related factor.
METHODSLiterature retrieval was conducted by using multi-databases for meta-analysis on Ketoconazole associated hepatotoxicity. The data were collected with a standardized form. Overall estimation of incidence of hepatotoxicity for specific study type was calculated by using a DerSimonian-Laird random-effects model owing to the substantial differences among the studies.
RESULTSTotally 204 eligible studies were included in the analysis. The incidence of Ketoconazole associated hepatotoxicity was 3.6%-4.2%. The dosage and duration specific subgroup analyses did not show any significant difference among groups, while the age specific subgroup analysis showed the incidence in children and people aged >60 years was 1.4% (95% CI: 0.5%-4.2%) and 3.2% (95% CI: 1.1%-8.7%) respectively. Additionally, the incidence of the hepatotoxicity was higher in people who had oral administration of ketoconazole beyond the provisions of the usage instructions, and the incidence was 5.7% (95% CI: 4.5%-7.2%).
CONCLUSIONKetoconazole associated hepatotoxicity was common. Off-label use might increase the risk of liver damage. Well-designed large sample studies are needed to identify the risk factors in future.